News | November 10, 2025
Venus Remedies expands ASEAN presence with new drug approvals in Vietnam
Venus Remedies now has 29 active product approvals in Vietnam alone
Venus Remedies now has 29 active product approvals in Vietnam alone
Early stage projects of up to Rs. 9 crore eligible for up to Rs. 5 crore assistance and later stage projects of up to Rs. 285 crore eligible for up to Rs. 100 crore assistance
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations
Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder in adults and pediatric patients aged six years and older
The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Tiotropium (as bromide monohydrate) 18 micrograms powder for inhalation in capsule
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
Subscribe To Our Newsletter & Stay Updated
